Cargando…

Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan

BACKGROUND: The role of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in the pandemic context of coronavirus disease 2019 (COVID-19) continues to be debated. Patients with hypertension, diabetes mellitus, chronic renal failure, cerebro-cardiovascular dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshihara, Fumiki, Ohtsu, Hiroshi, Nakai, Michikazu, Tsuzuki, Shinya, Hayakawa, Kayoko, Terada, Mari, Matsunaga, Nobuaki, Yasuda, Satoshi, Ogawa, Hisao, Ohmagari, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japanese College of Cardiology. Published by Elsevier Ltd. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989871/ https://www.ncbi.nlm.nih.gov/pubmed/35469713 http://dx.doi.org/10.1016/j.jjcc.2022.04.001

Ejemplares similares

First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics
por: Saito, Sho, et al.
Publicado: (2021)

Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan
por: Terada, Mari, et al.
Publicado: (2021)

Predicting respiratory failure for COVID-19 patients in Japan: a simple clinical score for evaluating the need for hospitalisation
por: Yamada, Gen, et al.
Publicado: (2021)

We Should Pay More Attention to Sex Differences to Predict the Risk of Severe COVID-19: Men Have the Same Risk of Worse Prognosis as Women More Than 10 Years Older
por: Matsushita, Yumi, et al.
Publicado: (2023)

Predictors of silent hypoxia in hospitalized patients with COVID-19 in Japan
por: Hayakawa, Kayoko, et al.
Publicado: (2022)

The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan
por: Togano, Tomiteru, et al.
Publicado: (2021)

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan
por: Matsunaga, Nobuaki, et al.
Publicado: (2020)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

1147. Regional Trends in Favipiravir and Steroid Use in the Treatment of COVID-19
por: Asai, Yusuke, et al.
Publicado: (2022)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Impact of regional heterogeneity on the severity of COVID-19
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

Predictive model of risk factors of High Flow Nasal Cannula using machine learning in COVID-19
por: Matsunaga, Nobuaki, et al.
Publicado: (2022)

Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan
por: Nomoto, Hidetoshi, et al.
Publicado: (2022)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
por: Endo, Mio, et al.
Publicado: (2020)

908. Evaluation of Blood Culture Submission Rates in Japan
por: Tajima, Taichi, et al.
Publicado: (2020)

Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study
por: Matsunaga, Nobuaki, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test
por: Suzuki, Michiyo, et al.
Publicado: (2023)

External validation and update of prediction models for unfavorable outcomes in hospitalized patients with COVID-19 in Japan
por: Yamada, Gen, et al.
Publicado: (2021)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Risk factors associated with asymptomatic hypoxemia among COVID-19 patients: a retrospective study using the nationwide Japanese registry, COVIREGI-JP
por: Akiyama, Yutaro, et al.
Publicado: (2022)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension
por: Kuzeytemiz, Mustafa, et al.
Publicado: (2022)

Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period
por: Shoji, Kensuke, et al.
Publicado: (2022)

Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan
por: Shoji, Kensuke, et al.
Publicado: (2022)

Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis
por: Shoji, Kensuke, et al.
Publicado: (2023)

The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19
por: Ekholm, M., et al.
Publicado: (2021)

Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities
por: Tomidokoro, Daiki, et al.
Publicado: (2023)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
por: Morales, Daniel R, et al.
Publicado: (2020)

Temporal trends in microbial detection during the COVID-19 pandemic: Analysis of the Japan surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) database
por: Endo, Akira, et al.
Publicado: (2023)

Effect of temperature on the infectivity of COVID-19
por: Ujiie, Mugen, et al.
Publicado: (2020)

Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control
por: Uemura, Yukari, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hekg4vscu28vj5f454lbenvhvn